Consistently, the survival curves of AML patients revealed a trend that U2AF1 mutations were significantly related to a shorter overall survival compared with those without a U2AF1 mutation by TCGA (p = 0.02; Fig. 1C). This evidence concerns the gene U2AF1 and acute myeloid leukemia.